Merck Sharp + Dohme Corp.

Schering Corporation

Schering-plough Corporation

Pharmacopeia Inc.

Salem Fevrier

Christopher W Boyce

Robert G Aslanian

Xianhai Huang

Kevin D McCormick

Anandan Palani

Phieng Siliphaivanh

Younong Yu

Joey Lee Methot

Ashwin Umesh Rao

Manuel De Lera Ruiz

Junying Zheng

Li Dong

David James Witter

Kevin J Wilson

Michael Berlin

David L Sloman

Pauline C Ting

Rongze Kuang

Jianhua Chao

Wei Zhou

Neng-Yang Shih

Joseph A Kozlowski

Lei Chen

Jie Wu

Umar Faruk Mansoor

Matthew H Daniels

Walter Won

Danielle Falcone

Ning Shao

Kathryn Ann Lipford

Brendan O'Boyle

Jongwon Lim

Raman Kumar Bakshi

Milana M Maletic

Pietro Mangiaracina

Chia-Yu Huang

Bo Liang

Henry M Vaccaro

Elizabeth Helen Kelley

Ravi Kurukulasuriya

Rong-qiang Liu

William Colby Brown

Ganesh Babu Karunakaran

Dong Xiao

Hongjun Zhang

Ling Tong

David Joseph Guerin

Purakkattle J Biju

Robert D Mazzola, Jr

Alessia Petrocchi

Xiao Chen

Catherine M White

Christian Fischer

Qin Jiang

Ron Ferguson

Corey E Bienstock

Jun Qin

Shuyi Tang

Huagang Lu

Pawan Dhondi

Ruiyan Liu

Judson E Richard

Sylvia Joanna Degrado

Ronald D Ferguson

Lisa Guise-Zawacki

Angie R Angeles

Jolicia Polivina Gauuan

Andrew J Leyhane

Jayanth Thiruvellore Thatai

Youngong Yu

Bidhan A Shinkre

Pietro Mangiarcina

Robert George Aslanian

Kevin D Mccormic

Joe Lee Method

Ronald D Ii Ferguson

Xiandai Huang

Purakkattle Johny Biju

Pawan K Dhondi

Brendan M O'BOYLE

Robert D Mazzola

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

The invention provides certain quinolines and aza-quinolines of the Formula (I), and their pharmaceutically acceptable salts, wherein E, J, J, J, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). 

In its many embodiments, the present invention provides a novel class of biaryl spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators

Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of biaryi spiroaminooxazoline analogues as modulators of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

In its many embodiments, the present invention relates to a novel class of phenylmorpholine and phenylthiomorpholine compounds useful as &#x3b1;2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the &#x3b1;2C adrenergic receptor agonists using such compounds or pharmaceutical compositions.

&#x3b1;2C adrenoreceptor agonists

Growing community of inventors

Cranford, NJ, United States of America

Salem Fevrier